首页 | 本学科首页   官方微博 | 高级检索  
检索        

CYP2C19*2、CYP2C19*3基因分型与急性缺血性脑卒中再发脑卒中的关系
引用本文:李孟超,柯琦玮,王大明.CYP2C19*2、CYP2C19*3基因分型与急性缺血性脑卒中再发脑卒中的关系[J].中国急救复苏与灾害医学杂志,2021(1).
作者姓名:李孟超  柯琦玮  王大明
作者单位:苏州大学附属第三医院常州市第一人民医院急诊科
基金项目:江苏省卫生和健康委员会2015年医改试点单位课题(编号:YG201513);常州市第九批科技计划应用基础研究项目(编号:CJ20190064)。
摘    要:目的探讨细胞色素P450药物代谢酶(CYP)2C19基因分型与氯吡格雷治疗的急性缺血性脑卒中患者再发脑卒中的关系。方法选取2018年5月—2018年12月常州市第一人民医院收治接受氯吡格雷治疗的159例急性缺血性脑卒中患者,检测患者入院后空腹外周血中CYP2C19*2,CYP2C19*3基因分型。对患者进行随访,随访截至2020年2月,观察再发脑卒中的情况,并分析CYP2C19*2,CYP2C19*3基因分型与再发脑卒中关系。结果随访时间14~22个月,平均随访时间为(18.2±1.5)个月,共7例患者失访,共20例(13.2%)患者复发缺血性脑卒中。再发脑卒中患者中CYP2C19*2 GG型及CYP2C19*3 GG型均低于无复发患者(P<0.05),CYP2C19*2 GA型,CYP2C19*2 AA型CYP2C19*3 GA型,CYP2C19*3AA型均高于无复发患者(P<0.05)。Kaplan-Meier法并Log-rank检验结果显示,CYP2C19*2 GG型无复发时间长于AA型,差异有统计学意义(Log-rank=6.759,P=0.034)。CYP2C19*3GG型无复发时间长于AA型,差异有统计学意义(Log-rank x2=8.660,P=0.013)。多因素Cox分析结果显示,糖尿病、氯吡格雷抵抗,CYP2C19*2及CYP2C19*3基因型是再发脑卒中影响因素(P<0.05)。结论在接受氯吡格雷治疗急性缺血性脑卒中患者中,CYP2C19*2及CYP2C19*3突变型再发脑卒中的风险明显增高。

关 键 词:细胞色素P450药物代谢酶2C19  氯吡格雷  急性缺血性脑卒中  再发脑卒中

Relationship between CYP2C19*2,CYP2C19*3 genotyping and recur-rent stroke in acute ischemic stroke
LI Mengchao,KE QIwei,WANG Daming.Relationship between CYP2C19*2,CYP2C19*3 genotyping and recur-rent stroke in acute ischemic stroke[J].China Journal of Emergency Resuscitation and Disaster Medicine,2021(1).
Authors:LI Mengchao  KE QIwei  WANG Daming
Institution:(Department of Mergency,Changzhou First People's Hospital,Changzhou 213000,China)
Abstract:Objective To investigate the relationship between cytochrome P450 drug metabolizing enzyme(CYP)2C19genotyping and recurrent stroke in treatment of clopidogrel in patients with acute ischemic stroke(AIS).Methods 159AlS patients,aged>18,were hospitalized and treated with clopidogrel.Sample of peripheral fasting venous blood werecollected at admission and underwent PCR by base quenching probe technique to test the genotypes of CYP2C19*2 and CYP2.The patients were lowed up for(18.2±1.5)months(14-22 months)to observe the recurrent stroke and ana-lyze the relationship between CYP2C19*2 and CYP2C19*3 genotyping and recurrent stroke.Results 7 patients werelost to follow-up and 20(13.2%)had recurrent ischemic stroke.CYP2C19*2CG and CYP2C19*3 CG were lower inthe patients with recurrent stroke than in patients without recurrence(P<0.05).The rates of CYP2C19*2 GA,CYP2C19*2AA,CYP2C19*3 GA,and CYP2C19*3 AA types were all significantly higher in the patients with recur-rent stroke than in those without recurrence(all P<0.05).Kaplan-Meier method and Log-rank test results showed thatCYP2C19*2GG type has no recurrence time longer than AA type,the difference is statistically significant(Log-rank X=6.759,P=0.034).CYP2C19*3 GG type has no recurrence time longer than A A type,the difference is statistically sig-nificant(Log-rank x=8.660,P=0.013).Multivariate Cox analysis showed that diabetes,clopidogrel resistance.CYP2C19*2 genotype and CYP2C19*3 genotype were influencing factors for recurrent stroke(all P<0.05).Conclusionln the AlS patients receiving clopidogrel the risk of recurrent stroke in CYP2C19*2 and CYP2C19*3 mutants is signifi-cantly increased.
Keywords:Cytochrome P450 drug metabolizing enzyme 2C19  Clopidogrel  Acute ischemic stroke  Recurrent stroke
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号